Identification of BRCA- and CHEK2-related breast cancer and ovarian cancer in women in outpatient oncology clinical practice

Authors

  1. Burdenko Main Military Clinical Hospital, Moskva, Russian Federation
  2. Moscow Medical - Social Institute named after Friedrich Haass, Moskva, Russian Federation

https://doi.org/10.35571/RMSJ.2019.1.002

Share: VK Telegram By e-mail

Full text

Abstract

Introduction. Currently breast cancer is considered a heterogeneous disease and spectrum of several biological subtypes. Ovarian cancer is also characterized by a variety of molecular genetic alterations. Both diseases remain the leading specific causes of death in age group 40-49 and 50-59 for females. Objective: to evaluate the frequency of mutations in the genes BRCA1/2 and CHEK2 in patients with breast cancer and patients with ovarian cancer, as well as in women with benign neoplasms of the mammary glands, and to analyze their clinical and morphological correlations with the disease characteristics in the routine clinical practice of an outpatient oncologist. Patients and Methods: Seventy-six women were included in the present analysis. All of them were observed by the oncologist in Consultative and diagnostic center of Burdenko Main Military Clinical Hospital (Moscow) between January 2016 and May 2019, and were divided in three groups: patients with breast cancer (n=20), patients with ovarian cancer (n=17) and control group of women with benign neoplasms of the mammary glands (fibrocystic mastopathy in 29, breast fibroadenoma in 11), with no history of any oncological disease. One patient has metachronous malignant neoplasms of independent (primary) multiple sites: breast and ovarian cancer. All women were genotyped for pathogenic germline mutations 185delAG, 300T>C (Cyse61Gly), 2080delA, 3819delGTAAA, 3875delGTCT, 4153delA, 5382InsC in the gene BRCA1, mutation 6174delT in the gene BRCA2 and mutations IVS2+1G>A, I157T and IVS2+1G>A in the gene CHEK2 by polymerase chain reaction real-time using a set “OncoGenetics” (LLC «Research and Production Company DNA-Technology», Russia, registration certificate № 2010/08415). Results: Pathogenic germline BRCA1 mutations were identified in 4 (20%) patients with breast cancer, 3 (17,6%) patients with ovarian cancer and 1 (2,5%) women with breast fibroadenoma. Pathogenic germline CHEK2 mutations were identified in 3 (15%) patients with breast cancer, all cases were represented by the I157T mutation. In the control group carriers of BRCA1 or BRCA2 mutations (n=2) were associated with early onset development of breast fibroadenoma in the age before 30 years. The risk of BRCA or CHEK2 mutated genes was significant higher in patients with breast cancer (45%, HR 9.0, 95% CI: 2.14 - 37.8) compared with the control group of women with benign breast tumors (5%, p <0.001). The risk of BRCA or CHEK2 mutations was also higher in patients with ovarian cancer (17.6%, HR 3.53, 95% CI: 0.65 – 19.26) compared with the control group (5%), but the difference did not reach significance (p=0.151). Genotyping BRCA and CHEK2 results were correlated (r = 0.423) with a family history: mutations were more often detected in women with a family history of cancer (42.9% versus 7.3%, p = 0.001). Women with identified mutations showed an increased risk of early onset cancer development before the age of 50 years (69.2%, HR 4.33, 95% CI: 1.64 - 11.36, p = 0.003) compared with wild-type carriers BRCA and CHEK2 genes (16%). The only case of primary multiple metachronous malignant tumors of the breast and ovaries, as well as cases of bilateral breast cancer lesions were detected only among carriers of BRCA1/2 mutations. The prevalence of aggressive high grade cancer was higher in patients with BRCA and CHEK2 mutations (63.6%, HR 2.45, 95% CI: 0.87 - 6.90) than in patients with wild type genes (47.1 %), however, the difference did not reach significance (p = 0.141). Conclusions: Our results have shown the relevance and value of identifying for BRCA- and CHEK2-related breast cancer and ovarian cancer in women in everyday clinical practice. The vast majority of cases of breast and ovarian cancer among carriers of BRCA1/2 and CHEK2 mutations are found in the working and reproductive age of women and are associated with unfavorable disease characteristics - high grade and lower survival.

Keywords

breast cancer, ovarian cancer, breast fibroadenoma, BRCA, CHEK2, age at diagnosis, grade tumor

Для цитирования:

Киричек С.Г., Киричек А.А., Корабельников Д.И. Выявление BRCA- и CHEK2-ассоциированных форм рака молочной железы и рака яичников у женщин в амбулаторной клинической практике врача-онколога. Российский медико-социальный журнал. 2019;1(1):22-30. https://doi.org/10.35571/RMSJ.2019.1.002

For citation:

Kirichek S., Kirichek A., Korabelnikov D. Identification of BRCA- and CHEK2-related breast cancer and ovarian cancer in women in outpatient oncology clinical practice. Russian Medical and Social Journal. 2019;1(1):22-30. (In Russian) https://doi.org/10.35571/RMSJ.2019.1.002

References

  1. Krykov EV, Chaplyuk AL, Koryakin SV et al. General approaches to the formulation of the diagnosis of malignant neoplasm in the conduct of military medical examination. Voenno-meditsinskii jurnal [Military Medical Journal]. 2017;338(12):13-17 (In Russ.).
  2. Zaridze DG, Kaprin AD, Stilidi IS Dynamics of morbidity and mortality from malignant tumors in Russia. J Voprosy onkologii [Problems in oncology]. 2018;64(5):578-591 (In Russ.).
  3. Semiglazov VF. Strategy of treatment for breast cancer based on biological subtypes’ identification. J Voprosy onkologii [Problems in oncology]. 2011;57(5):542-552 (In Russ.).
  4. Bateneva YI, Filippova MG, Tyulyandina AS et al. High rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in Russian ovarian cancer patients. J Opuholi ženskoj reproduktivnoj sistemy [Tumors of female reproductive system]. 2014;(4):51-56. (In Russ.). doi: https://doi.org/10.17650/1994-4098-2014-0-4-51-56
  5. Grigoruk OG, Pupkova EE, Bazulina LM, Lazarev AF. Serous ovarian carcinoma. Cytological and immunocytochemical and molecular genetic diagnostics. J Opuholi ženskoj reproduktivnoj sistemy [Tumors of female reproductive system]. 2016;12(2):70-76. (In Russ.). doi: https://doi.org/10.17650/1994-4098-2016-12-2-70-76
  6. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278(15):1242-1250. PMID: 9333265.
  7. Bateneva EI, Meshcheryakov AA, Lyubchenko LN et al. Frequencies of eleven BRCA1 and BRCA2 mutations in random sample of russian breast cancer patients. Uralsky meditsinsky jurnal [Ural Medical Journal] 2011;3(81):69-73. (In Russ.).
  8. Christgen M, Länger F, Kreipe H. Histological grading of breast cancer. Pathologe. 2016;37(4):328-36. (In Germ.). doi: https://doi.org/10.1007/s00292-016-0182-8
  9. Kurman RJ, Carcangiu ML, Herrington CS, Young RH WHO classification of tumours of female reproductive organs, 4th ed. IARC, Lyon, 2014.
  10. Nelson HD, Pappas M, Cantor A et al. Risk Assessment, Genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;322(7):666-685. doi: https://doi.org/10.1001/jama.2019.8430.
  11. Tang EY, Trivedi MS, Kukafka R et al Population-based study of attitudes toward BRCA genetic testing among Orthodox Jewish women. Breast J. 2017;23(3):333-337. DOI: https://doi.org/10.1111/tbj.12736.
  12. Kaprin AD,. Starinskiy VV, Petrova GV. Malignant tumors in Russia in 2017 (morbidity and mortality). Moscow: MNIOI im. P.A. Gertsena - filial FGBU “NMIRTS” Minzdrava Rossii, 2018. 250 p. (In Russ.).
  13. Ford D, Easton DF, Stratton MR et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Gen 1998;62(3):676-89. doi: https://doi.org/10.1086/301749. PMID: 9497246.
  14. Eerola H, Heinonen M, Heikkilä P et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2008;10(1):17
  15. Robson M, Levin D, Federici M et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 1999;91(24):2112 7. doi: https://doi.org/10.1093/jnci/91.24.2112. PMID: 10601383.
  16. Graeser MK, Engel C, Rhiem K et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009;27(35):5887 5892. doi: https://doi.org/10.1200/JCO.2008.19.9430. PMID: 19858402.
  17. Kirichek AA, Lyubchenko LN, Matveev VB. Risk-adapted approach to prostate cancer screening. Onkourologiya [Cancer Urology]. 2018;14(2):109-121. (In Russ.). doi: https://doi.org/10.17650/1726-9776-2018-14-2-109-121
  18. Kopnin BP. Tumor suppressor and mutated genes. In: Zaridze DG. Tumorigenesis. Moscow: Medicina, 2004:125-126. (In Russ.).
  19. Imyanitov EN. Molecular diagnosis in oncology. Moleculyarnaya biologiya [Molecular Biology]. 2008;42(5):687-698. (In Russ.).

About the authors

  • Svetlana Kirichek, Burdenko Main Military Clinical Hospital, Moskva, Russian Federation

    Burdenko Main Military Clinical Hospital — Surgery and Oncology Dept, Consultative and Diagnostic center, resident, M.D.

  • Daniil Korabelnikov, Moscow Medical - Social Institute named after Friedrich Haass, Moskva, Russian Federation

    Moscow Medical - Social Institute named after Friedrich Haass — Rector

How to Cite

Identification of BRCA- and CHEK2-related breast cancer and ovarian cancer in women in outpatient oncology clinical practice. (2019). Russian Medical and Social Journal, 1(1), 22-30. https://doi.org/10.35571/RMSJ.2019.1.002
Views: 5 JATS XML

License

Copyright (c) 2019 Russian Medical and Social Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

ISSN (Print) 2658-7726 ISSN (Online) 2658-7718